Sorafenib (co-developed and co-marketed by Bayer and Onyx Pharmaceuticals as Nexavar) is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma) advanced primary liver cancer (hepatocellular carcinoma) and radioactive iodine resistant advanced thyroid carcinoma.
This page contains content from the copyrighted Wikipedia article "Sorafenib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
